DocumentsDate added
Research article:-
Vijay Ramegowdanapura Malleshappa1,Jayasheelan Mambally Rachaiah2* & Niranjan Mambally Rachaiah3
Affiliations:-
1MD (General Medicine)., DNB (Nephrology), Consultant Nephrologist, Apollo BGS Hospitals, Mysore, Karnataka, India.
2MD (Internal Medicine)., DNB., MNAMS, Assistant Professor, Department Of Medicine, Mysore Medical College & Research Institute, Mysore, Karnataka, India.
3MD (Internal Medicine)., DNB., MNAMS, Assistant Professor, Department Of Medicine, Hassan Institute of Medical Sciences, Hassan 573201 Karnataka, India.
Abstract:
Background: Tacrolimus is an immunosuppressive agent which improves clinical outcomes in kidney transplant recipients. The risk of tacrolimus nephrotoxicity was higher in patients with high systemic exposure of tacrolimus during the early post transplant period. Hence we made an effort to monitor tacrolimus levels and related nephrotoxicity.
Aims: To find out the incidence of tacrolimus nephrotoxicity and to correlate with tacrolimus levels.
Materials and Methods: A prospective cross sectional study. Tacrolimus levels were estimated and looked for nephrotoxicity by renal biopsy. Pearson’s Chi Square test was applied.
Results: Tacrolimus level estimations done on 135 recipients. The average mean level was 6.9±1.8 ng/ml. Early tacrolimus toxicity was diagnosed in two (22.2%) recipients, while most (4–44.4%) were in the 4–6 months follow-up period. More rejection seen in recipients having lower mean tacrolimus levels in the early (≤30days) post transplant period. Four (44.4%) patients with tacrolimus toxicity had acute rejection. During
30 days there were two events of toxicity among patients having mean level >10 ng/ml.
Conclusion:No significant correlation found between average tacrolimus trough levels and nephrotoxicity. However patients with nephrotoxicity had high tacrolimus trough levels just before the event. Hence nephrotoxicity cannot be predicted based on mean tacrolimus levels alone.
Key Words: Tacrolimus Nephrotoxicity, Renal Transplantation, Graft Rejection.
References:
1.Fung JJ. Tacrolimus and transplantation:a decade in review. Transplantation 2004;77:S41.
2.Shapiro R, Young JB, Milford EL, et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 2005;5:874.
3.Gruessner RWG, Burke GW, Stratta R, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996;61:261.
4.Plosker GL, Foster RH: Tacrolimus: a further update of its pharmacology and therapeutic use in organ transplantation. Drugs 2000;59:323.
5.Undre NA, van Hooff J-P, Christiaans A, et al: Transplant Proc 1999;31:296.
6.Schwart M, Holst B, Facklam D, Buell D and The US Multicenter FK506 Dose Optimization Study Group. FK506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. Transplant Proc 1995;27:1107.
7.Winkler M, Wonigeit K, Undre N, et al. Comparison of plasma vs whole blood as matrix for FK506 drug level monitoring. Transplant Proc 1995;27:822-5.
8.Takahara S, Kokado Y, Kameoka H, et al. Monitoring of FK506 blood levels in kidney transplant recipients. Transplant Proc 1994;26:2106-8.
9.Kershner R, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62;920-6.
10.Undre NA, van Hooff J, Christianns M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999;31:296-8.
11.Backman L, Levy MF, Klintmalm, and the FK506 Multicentre Study Group. Whole-blood and plasma levels of FK506 after liver transplantation: Results from the US Multicentre Trial. Transplant Proc 1995; 27:1124.
12.Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Transplantation 1994;57:519-25.
13.Jain AB, Todo S, Fung JJ, et al. Correlation of rejection episodes with FK506 dosage, FK506 level and steroids following primary orthotropic liver transplantation. Transplant Proc 1991;23:3023-5.
14.Japanese FK506 Study Group. Japanese Study of FK506 on kidney transplantation: The benefit of monitoring the whole blood FK506 concentration. Transplant Proc 1991;23:3085-8.
15.Ochiai T, Ishibashi M, Fukao K, et al. Japanese multicenter studies of FK506 in renal transplantation. Transpl Proc 1995;27:50.
16.Abu-Elmagd K, Fung JJ, Alessiani M, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991;52:71.
17.Takahara S. Efficacy of FK506 in renal transplantation. Ann N Y Acad Sci 1993;696:235.
18.Porayko MK, Textor SC, Krom RAF, et al. Nephrotoxic effects of primary immunosuppression with FK506 and cyclosporine regimens after liver transplantation. Mayo Clinic Proc 1994;69:105.
19.McCauley J, Fung J, Jain A, Todo S, Starzl TE. The effects of FK506 on renal function after liver transplantation. Transpl Proc 1990;22:17.
Article citation:-
Vijay R M, Jayasheelan M R, Niranjan M R. A correlative study of tacrolimus levels with nephrotoxicity in post renal transplanted patients. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1130-1136.
Copyright © 2013 Vijay R M, Jayasheelan M R & Niranjan M R. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
S Kannan*, PM Anwar Sadath1, J Nandhakumar2, N Senthilkumar3 , Aniket** Kumar & MG Tyagi**
Affiliation:-
*, 1, 3 Department of Pharmacy Practice, JKKMMRF CP, Namakkal- 638 183, Tamil Nadu, India.
2 Department of Pharmacology, MNR Colllege of Pharmacy, Sangareddy-, A.P, India.
** Department of Pharmacology, Christian Medical College, Vellore - 632 002,Tamil Nadu, India.
Abstract:
Background & objectives: Pre-eclampsia is a syndrome characterized by hypertension and proteinuria that is occurring during the 2nd and 3rd trimester of pregnancy or after the 20th week of gestation. It can cause disseminated intravascular coagulation, vasospasm, sodium retention, and seizures; the occurrence of seizures in pre-eclamptic women marks the onset of eclampsia.
Methods: This study is conducted in BM hospital Pulikkal, Malappuram, Kerala. A total of 80 pre-eclamptic patients were enrolled in the treatment program. A prospective observational study was carried out and compared the safety and efficacy of Methyldopa and Nifedipine on maternal blood pressure as well as maternal and fetal outcomes in patients with pre-eclampsia, in which 40 patents were taking Methyldopa and the remaining 40 patients were taking Nifedipine.
Results: The study population is divided into two groups viz., Nifedipine and Methyldopa group. The reduction of systolic and diastolic blood pressure was greater in Nifedipine group than in Methyldopa group. The P value of systolic blood pressure after first review, second review and BP after 42 days was 0.001, which was significant. P value of decreasing blood pressure on first review and second review were 0.002 and 0.001 respectively, which was also significant. The reduction of proteinuria values was greater in Nifedipine group than Methyldopa group. The P value of proteinuria values after second review was 0.001, which was significant. P value of decreasing proteinuria value on first and second review was 0.001, which was also significant
Interpretation & Conclusions: Nifedipine administration resulted in beneficial effects on reducing both systolic and diagnostic blood pressure in pre-eclamptic patients. The Methyldopa also has considerable effect, but not to the extent of Nifedipine.
Key words:- Hypertension, Methyldopa, Nifedipine,Preeclampsia , Proteinuria, Pregnant.
References:-
1.Choudhary P. Eclampsia,. A hospital based retrospective study, Kathmandu University Medical Journal 2003; 1 (4):237-41.
2.Perkin Elmer, Early detection of pre-eclampsia vol.1, (2004), 1-18.
3.Dekker G., Sibai B. Primary, secondary, and tertiary prevention of preeclampsia. Lancet. 2001;357:209–15.
4.Eden TW. Eclampsia. Journal of Obstetrics and Gynaecology of the British Empire 1922;29: 386–401.
5.Christin L. Roberts, Hypertensive disorder, a population based study 2005;182 (7): 332-5.
6.1999 World Health Organization–International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151–183
7.Duley L. Pre-eclampsia, eclampsia and hypertension, Online version of BMJ Clinical Evidence(2008).
8.Fiona Lyalla. The vascular endothelium in normal pregnancy and pre-eclampsia, reviews of reproduction 1996; 1:107-14.
9.Meyeon Park and Ursula C. Breuster, Management of pre-eclampsia (hospital physician) 2007:25-31.
10.Rolfes DB, Ishak KG.Liver disease in toxemia of pregnancy. Am J Gastroenterol. 1986;81:1138–1144.
11.Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA.Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol.1993;169:1000–6.
12.Weinstein L Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 1982; 142:159–67.
13.Khedun SM, Moodley J, Naicker T, Maharaj B. Drug management of hypertensive disorders of pregnancy. Pharmacol Ther 1997;74: 221-58.
14.Tyag MG, MA Kamdod, L J eyaseelan. Arginine vasopressin potentiates methyldopa induced hypotension in anesthetized Wistar rats. Indian journal of physiology and pharmacology 05/1993; 37(2):167-8.
15.Rubeea Aziz, Pre-eclampsia and lipid profile, Pak J Med Sci 2007;.23(5):751-4.
16.Fenakel K, Fenakel G, Appelman Z, Lurie S, Katz Z, Shoham Z. Nifedipine in the treatment of severe preeclampsia. Obstet Gynecol 1991.
Article citation:-
Tyagi et al. A Prospective study comparing methyldopa and nifedipine for the treatment of hypertension in patients with pre-eclampsia in a tertiary care hospital, Kerela, India. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1123-1129.
Copyright © 2013 Tyagi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:-
*1Sushma Katkuri, 1Nithesh Kumar, 1Pravinpisudde, & 2Mallika Anjum
Affiliation:-
1Assistant Professor,2Final Year MBBS student, Department of Community Medicine, Deccan College of Medical Sciences, Hyderabad, India.
Abstract:
A study to determine awareness of pregnancy related complications among pregnant women in Esra Hospital in Hyderabad, India.
Background: Giving birth to an off-spring is the most beautiful experience for a woman. Yet in most of the world, pregnancy and childbirth is a tough journey. Every pregnant woman faces the risk of sudden, unpredictable complications that could end in death or injury to herself or to her infant. Aims & Objectives: To determine awareness of pregnancy related complications among pregnant women. Materials & Methods: A hospital based cross-sectional study was conducted in two hospital areas of Deccan College of Medical college, Hyderabad. The study was carried out in the month of May 2011-june 2011 for duration of 2 months. The study subjects were all pregnant women attending the Obstetrics and Gynecology OPD of Owaisi hospital and Esra hospital. Results: Only 10% were having knowledge about the high risk pregnancy. Anemia was seen in 68% of the selected subjects. Swelling over feet was noted in one fourth of respondents and blood pressure of 140/90mmHg and above was seen in 36% of the subjects. Conclusion: Lack of awareness about obstetric danger signs was related to low level of education about the danger signs of pregnancy.
Key Words:- Antenatal care, Danger signs, High risks, Pregnancy.
References:-
1.Ransom EI and Yinger NV. Making motherhood safer, overcoming obstacles on the pathway to care. Population reference Bureau, February 2002.Available at: http://www.prb.org/pdf/Mak MotherhdSafer_Eng.pdf.
2.United Nations Population Fund (UNFPA), Maternal Mortality Declining in Middle income Countries; Women Still Die in Pregnancy and Childbirth in Low-income Countries (Oct. 12, 2007), available athttp://www.unpf.org/news/news.
3.Roopa Bakshi, UNICEF unveils new tool to combat maternal mortality in India, UNICEF, Apr. 6, 2006, at http://www.unicef.org/infobycountry/india33208
4.U.N. Committee on the Elimination of All Forms of Discrimination Against Women (CEDAW Committee), Consideration of Reports Submitted by States Parties Under Article 18 of the Convention on the Elimination of All Forms of Discrimination Against Women, Initial Report of States Parties: India, para. 221, UN Doc .CEDAW/C/IND/1 (1999).
5.UNFPA, Emergency Obstetric Care: Checklist for Planners 1 (2002), available at http://www.unfpa.org/upload lib_pub_file/150_filename_checklist_MMU.pdf.
6.The World Health Report 2005. Make every mother and child count. Geneva, World Health organization, 2005.
7.WHO, Maternal Mortality: Making Pregnancy Safer (2008), at http://www.who.intwho.int.
8.A.Singh, AK.Arora”The changing profile of pregnant women and quality of antenatal care in rural North India. Short article. Indian journal of community medicine 2007 April;32(2):135-6.
9.Aggarwal A, Pandey A, Bhattacharya BN. Risk factors for maternal mortality in Delhi slums: a community-based case-control study. Indian Journal of Medical Sciences. 2007 Sep;61(9):517-26.
10.Rizk MA, Abdel-Aziz F, Ashmawy AA, Mahmoud AA, Abuzeid TM Knowledge and practices of pregnant women in relation to the intake of drugs during pregnancy. The Journal of Egyptian Public Health Association1993; 68(5-6):567-91.
11.Zulfia Khan, Saira Mehnaz, Najam Khalique, Mohd Athar Ansari, and Abdul Razzaque Siddiqui. Poor Perinatal Care Practices in Urban Slums: Possible Role of Social Mobilization Networks. Indian Journal of Community Medicine. 2009 April; 34(2): 102–7.
12.Anya SE, Hydara A, Jaiteh LE. Antenatal care in The Gambia: missed opportunity for information, education and communication. BMC Pregnancy Childbirth. 2008 Mar 7;8:9. doi: 10.1186/1471-2393-8-9.
13.Al-Nahedh N. Sociodemographic variables affecting the health seeking behaviour of mothers in a saudi community. Journal of Family and Community Medicine. 2004 Jan;11(1):3-9.
14.Pallikadavath S, Foss M, Stones RW. Antenatal care: provision and inequality in rural north India. Social Science & Medicine. 2005 Mar; 60(6):1409.
15.Pembe AB, Carlstedt A, Urassa DP, Lindmark G, Nyström L, Darj E. Quality of antenatal care in rural Tanzania: counselling on pregnancy danger signs. BMC Pregnancy Childbirth . 2010 Jul 1;10:35. doi: 10.1186/1471-2393-10-35.
16.Hoque M, Hoque ME. Knowledge of danger signs for major obstetric complications among pregnant KwaZulu-Natal women: implications for health education. Asia Pacific Journal of Public Health. 2011 Nov; 23(6):946-56. Doi: 10.1177/1010539511428698.
17.Cigarette smoking knowledge, attitudes, and practices of patients and staff at a Perinatal substance abuse treatment center suboptimal knowledge of smoking health risks Afr.J Reprod Health 2012 Mar;16(1):55-60.
18.Adusi-Poku Y, Edusei AK, Bonney AA, Tagbor H, Nakua E, Otupiri E. Pregnant women and alcohol use in the Bosomtwe district of the Ashanti region-Ghana. African Journal of Reproductive Health. 2012 Mar;16(1):55-60.
Article citation:-
Katkuri Sushma et al. A study to determine awareness of pregnancy related complications among pregnant women in Esra hospital in Hyderabad, India. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1250-1255.
Copyright © 2013 Katkuri Sushma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
Dr.Girishbabu R J1*, Dr.Prakash R1 & Dr.Prashanth H V2
Affiliation:- 1 Assistant Professor, 2 Professor ,Department of Microbiology, Sri Siddhartha Medical College, Tumkur- 572107, Karnataka, India.
Abstract: Background: Urinary tract infections are among the most common bacterial infections that lead patients to seek medical care. The incidence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae have been steadily increasing over the past few years resulting in limitation of therapeutic options. Aims & Objectives: The aim of the study was to isolate, identify and to establish the antimicrobial susceptibility pattern of the pathogens responsible for urinary tract infections and also to determine the extended spectrum beta lactamase production of Escherichia coli and Klebsiella pneumoniae. Settings and design: Hospital based Prospective study. Materials & Methods: The study includes 3060 clinically suspected cases of urinary tract infection over a period of one year. Isolates were identified by conventional methods. Isolated Escherichia coli and Klebsiella pneumoniae which showed resistance to cefotaxime and ceftazidime were tested for extended spectrum beta lactamase production by phenotypic confirmatory test as proposed by the Clinical and Laboratory Standards Institute document. Statistical Analysis: The results were analyzed using mean, median and Chi-square (χ2) test. Results: Of the 3060 urine samples processed 990 (32.35%) samples yielded various bacterial isolates. Extended spectrum beta lactamase production was observed in 174 (38%) of Escherichia coli isolates and in 102 (42%) of Klebsiella pneumoniae isolates. Conclusion: Our results showed Escherichia coli as predominant organism, followed by Klebsiella pneumoniae causing urinary tract infection. Klebsiella pneumoniae were found to be more extended spectrum beta lactamase producer when compared to Escherichia coli.
Key Words:- Escherichia coli, Extended Spectrum Beta Lactamase, Klebsiella pneumoniae, Urinary tract infection.
References:-
1.Noor N, Ajaz M., Rasool SA., Pirzada ZA. Urinary tract infections associated with multidrug resistant enteric bacilli, characterization and genetical studies. Pak J Pharm Sci. 2004;17: 115-123
2.Ronald AR, Pattulo MS. The natural history of urinary infection in adults. Medical clinics of North America 1991; 75: 299-312.
3.Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis. 2004; 38: 1150–1158.
4.Sobel JD, Kaye D. Urinary tract infections. In: Mandel GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th ed. Newyork: Churchill Livingstone; 2000. p. 773-805.
5.Newell A, Riley P, Rogers M. Resistance patterns ofurinary tract infections diagnosed in a genitourinary medicine clinic. Int J STD AIDS 2000; 11: 499-500.
6.Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 2001; 47: 773-80.
7.Cao V, Lambert T, Nhu DQ, Loan HK, Hoang NK, Arlet G, Courvalin P. Distribution of extended-spectrum β-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob Agents Chemother 2002; 46: 3739-43.
8.Bradford PA. Extended-spectrum beta-lactamase in the 21st century: characterization, epidemiology, and detection of this important resistance threat, Clin Microbiol Rev 2001; 14: 933-51.
9.Cormican M, Morris D, Corbett-Feeney G, Flynn J. Extended-spectrum beta-lactamase production and fluoroquinolone resistance in pathogens associated with community-acquired urinary tract infection. Diagn Microbiol Infect Dis 1998; 32: 317-319.
10.Bush K, Jacoby GA (2010). An updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54(3): 969-76.
11.Babypadmini S, Appalaraju B. Extended spectrum beta lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae- prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004; 22(3): 172-4.
12.Bou G, Cartelle M, Tomas M, Canle D, Molina F, Moure R, Eiros JM, Guerrero A. Identification and broad dissemination of the CTX-M-14 β-lactamase in different Escherichia coli strains in the Northwest area of Spain. J Clin Microbiol 2002; 40: 4030-6.
13.Koneman EW, Allen SD, Janda WM, Winn WC, Schreckenberger PC, Procop GW, et al, editors. Introduction to microbiology- part II: urinary tract infections. In: Koneman’s color atlas and textbook of diagnostic microbiology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2006. p. 82-87.
14.Forbes BA, Sahm DF, Weissfeld AS, editors. Infections of the urinary tract In: Bailey & Scotts diagnostic microbiology. 11th ed. St.Louis: Mosby; 2002. p. 927-938.
15.Collee JG, Duguid JP, Fraser AG, Marmion BP, Simmons A. Laboratory strategy in the diagnosis of infective syndromes. In: Collee JG, Fraser AG, Marmion BP, Simmons A, editors. Mackie and McCartney, practical medical microbiology. 14th ed. Edinburgh: Churchill Livingstone; 1996. p. 84-90.
16.Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 17th informational supplement. CLSI/NCCLS document M100-S17. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania; 2007; 27(1): 1-177.
17.Water G, Harrison B, and Kunin G. Urinary tract infection. N. Eng Med. J 1996; 248-50.
18.Urinary Tract Infection. Adam healthcare center. [Online]. 2007 [cited 2007 Sept 16]; Available from: URL:http://www.about .com
19.Das RN, Chandrashekhar TS, Joshi HS, Gurung M, Shrestha N, Shivananda PG. Frequency and susceptibility profile of pathogens causing urinary tract infections at a tertiary care hospital in Western Nepal. Singapore Med J 2006; 47(4): 281-5.
20.Mohanty S, Kapil A, Das BK, Dhawan B. Antimicrobial resistance profile of nosocomial uropathogens in a tertiary care hospital. Indian J Med Sci 2003; 57: 148-54.
21.Anbumani N, Mallika M. Antibiotic resistance pattern in uropathogens in a tertiary care hospital. Indian J Practising Doctor 2007; 4(1): 204-7.
22.Shobha KL, Rao GS, Rao S, Sreeja CK. Prevalence of extended spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella and Citrobacter species and their antimicrobial susceptibility pattern in a tertiary care hospital. Indian J Practising Doctor 2007; 3(6): 1-2.
23.Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC hospital Aligarh, India. Ann Clin Microb Antimicrobials 2007; 6: 4.
24.Samaha-Kfoury JN, Araj GF. Recent developments in β-lactamases and extended spectrum β-lactamases. BMJ 2003; 327: 1209-13.
Copyright © 2013 Girishbabu R J, Prakash R & Prashanth H V. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case report:-
*1Premraj Jadhav,2Sharad Acharya & 3Ketaki A .Patil.
Affiliation:-
1Professor,2Senior lecturer,3Postgraduate student, Department of Prosthodontics, Tatyasaheb Kore Dental College and Research Centre, New Paragon, Dist. Kolhapur- 416137,India.
Abstract: -
The problem of stability and retention of mandibular complete dentures is far from a solution that is universally satisfactory, smaller the number of mandibular teeth that remain, the more thoughtfully these teeth should be treated. Overdenture serves as the conservative prosthodontic treatment option in such cases. Also the retention and stability of such prosthesis is greatly enhanced by a bar connecting the abutments. Custom bar supported overdenture is a good alternative treatment modality because of its improved retention, stability, better chewing efficiency and also decrease in alveolar bone resorption. On the other hand, the immediate denture therapy for replacement of anterior missing teeth is expected and frequently demanded by appearance conscious people. The immediate denture enables them to engage in social activities and maintains physical and social well being of the patient. This case report presents the management of a patient with a bar retained mandibular overdenture opposing maxillary interim immediate denture.
Key Words:- Overdenture, bar joint,immediate denture, attachment.
References:
1.Tushar R, Suhasini J N. Rhabilitation of an edentulous patient with overdenture using magnetic attachments- A Case Report JIDA 2012; 6(2):142-4.
2.Harold W. Preiskel. Precision Attachments in Prosthodontics. Vol 1 Quintessence publishing: Co. 1984.
3.Thayer H.H, Caputo A.A. Occlusal force transmission by overdenture attachments.J Prosthet Dent 1979; 41: 266-71.
4.Morrow RM. Handbook of immediate overdentures. St. Louis: Mosby;1978:48.
5.Eugen J. Dolder, Dr.Med. Dent The bar joint mandibular denture. J Prosthet Dent 1961;11:689-707.
6.Sherring LM, Martin P : Attachments for prosthetic dentistry : Introduction and application. Quintessence publishing: 1st ed.
Article citation:-
Premraj Jadhav, Sharad Acharya & Ketaki A .Patil. Bar retained mandibular overdenture opposing maxillary complete immediate denture - A Case Report. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 June; 31(31): 1209-1213.
Copyright © 2013 Cemil Kavalci et al. This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.